Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study
NCT ID: NCT02644044
Last Updated: 2015-12-31
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
EARLY_PHASE1
Total Enrollment
30 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-01-31
Study Completion Date
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Multiple sclerosis (MS) is characterized pathologically by demyelination, axonal loss, and glial scar formation. Clinically, most patients have a relapsing-remitting course of MS (RRMS) that over time may become progressive without remissions - a secondary progressive MS (SPMS). About 15% of patients have a progressive course from onset which is called primary progressive (PP).
Currently, there is no approved treatment for PPMS and for SPMS only therapy with mitoxantrone showed mild effect. Thus, more effective therapies need to be developed for treatment of SPMS and PPMS.
Methotrexate (MTX), an anti-metabolite, has been in clinical use since 1948 when it was found to produce temporary remission of acute childhood leukemia.
There are accumulating evidences that in progressive MS patients there are follicular lymphoid structures in the meninges and in the Virchow-Robin spaces. Therefore, intrathecal therapy may target the pathological follicular lymphoid activity.
The safety of intrathecal MTX (ITMTX) has been demonstrated by its widespread use in treating lymphoproliferative diseases and leptomeningeal metastases. Sadik et. Al. reported about the feasibility and safety of using intrathecal methotrexate (ITMTX) as a treatment for unresponsive patients with progressive forms of MS. In their open label study they found that ITMTX may have a beneficial effect in progressive forms of MS and that it was well tolerated with no serious adverse events.
The investigators aim is to evaluate the efficacy , safety and tolerability of intrathecal methotrexate administration every 3 months in progressive 30 patients with progressive MS. The investigators will evaluate clinical, laboratory evaluation of the blood and cerebrospinal fluid as well as the MRI scans of the participants. Each patient will be treated 4 times for 1 year with the option to continue for another 1 more year with the same protocol.
Currently, there is no approved treatment for PPMS and for SPMS only therapy with mitoxantrone showed mild effect. Thus, more effective therapies need to be developed for treatment of SPMS and PPMS.
Methotrexate (MTX), an anti-metabolite, has been in clinical use since 1948 when it was found to produce temporary remission of acute childhood leukemia.
There are accumulating evidences that in progressive MS patients there are follicular lymphoid structures in the meninges and in the Virchow-Robin spaces. Therefore, intrathecal therapy may target the pathological follicular lymphoid activity.
The safety of intrathecal MTX (ITMTX) has been demonstrated by its widespread use in treating lymphoproliferative diseases and leptomeningeal metastases. Sadik et. Al. reported about the feasibility and safety of using intrathecal methotrexate (ITMTX) as a treatment for unresponsive patients with progressive forms of MS. In their open label study they found that ITMTX may have a beneficial effect in progressive forms of MS and that it was well tolerated with no serious adverse events.
The investigators aim is to evaluate the efficacy , safety and tolerability of intrathecal methotrexate administration every 3 months in progressive 30 patients with progressive MS. The investigators will evaluate clinical, laboratory evaluation of the blood and cerebrospinal fluid as well as the MRI scans of the participants. Each patient will be treated 4 times for 1 year with the option to continue for another 1 more year with the same protocol.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Protocol Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study
Introduction Multiple sclerosis (MS) is characterized pathologically by demyelination, axonal loss, and glial scar formation. Clinically, most patients have a relapsing-remitting course of MS (RRMS) that over time may become progressive without remissions - a secondary progressive MS (SPMS). About 15% of patients have a progressive course from onset which is called primary progressive (PP) (1). In the past decades, several treatments have been approved mainly for the use in RRMS.
Treatments for SPMS may be still effective for the early phase of this course, but it become ineffective for the later phase of SPMS (2,3) For PPMS, there is currently no approved treatment. Thus, more effective therapies need to be developed for treatment of SPMS and PPMS.
Methotrexate (MTX), an anti-metabolite, has been in clinical use since 1948 when it was found to produce temporary remission of acute childhood leukemia. Methotrexate irreversibly binds to and inhibits dihydrofolate reductase, inhibiting the formation of reduced folate, and thymidylate synthetase, resulting in inhibition of purine and thymidylic acid synthesis, thus interfering with DNA synthesis, repair, and cellular replication.
Because of its indirect immunosuppressive effects, MTX is used in treating autoimmune conditions such as rheumatoid arthritis and psoriasis (4). Low dose oral MTX (7.5 mg weekly) was found to be mildly effective, in slowing the deterioration in patients with SPMS (5).
There are accumulating evidences that in progressive MS patients there are follicular lymphoid structures in the meninges and in the Virchow-Robin spaces (8). These follicles are enriched in lymphocytes and dendritic cells which may drive the CNS inflammatory responses in the disease. This CNS restricted immune response may be unaffected by systemic immunomodulation and immunosuppressive therapies. Therefore, intrathecal therapy may target the pathological follicular lymphoid activity.
The safety of intrathecal MTX (ITMTX) has been demonstrated by its widespread use in treating lymphoproliferative diseases and leptomeningeal metastases (9). Sadik et. Al. reported about the feasibility and safety of using intrathecal methotrexate (ITMTX) as a treatment for unresponsive patients with progressive forms of MS (10). In their open label study they found that ITMTX may have a beneficial effect in progressive forms of MS and that it was well tolerated with no serious adverse events.
In the Last year the investigators have treated 8 patients with IT MTX according to the proposed protocol. Until now these patients receive 1-3 therapies of IT MTX without significance adverse event. The adverse event was were reported were: fatigue for several days post therapy and mild headache.
Objective The investigators aim is to evaluate the efficacy , safety and tolerability of intrathecal methotrexate administration in progressive MS patients.
Methods Study Population 30 progressive MS patients Inclusion Criteria
* Age 18-750 years
* Clinically definite diagnosis of MS according to McDonald criteria 2010.
* Progressive disease form defined by confirmed expanded disability status scale (EDSS) progression without relapse by at least 0.5 point or greater in the six months prior to enrollment.
Exclusion criteria
* Pregnancy
* Active infection
* Significant associated medical condition such as malignancy, heart disease or concurrent other autoimmune condition.
* Known allergy to MTX.
* WBC\<4000 cells/µL
* Lym\<800 cells/µL
* Treated with fingolimod or natalizumab 3 months prior to enrollment
Treatment The physician will administer 12.5 mg of MTX diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle. These doses are standard doses of IT treatment with MTX.
Treatments will be scheduled 3 months apart for 1 year .A tota of 4 treatments in a 1 year.
A CBC with differential will be obtained before each treatment to assess the level of hematological suppression.
Evaluation A. Patients will be evaluated every 3 months by a physician other then their treating physician with the following: Kurtzke Expanded Disability Status Scale (EDSS). 25 FW , 9 PHT, Symbol Digit Modalities Test (SDMT), fatigue scale (FSS) and depression scale (BDI). In each of the visits the patient will be asked about adverse events (AE) and will be instructed to report us every AE/ medical complain he will experience between visits.
AEs will be followed until resolution or through completion of the study, whichever comes first. All Serious adverse events (SAEs) will be followed until event resolution, until the condition stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up. The investigator is responsible for ensuring that follow-up includes any supplemental investigations as may be reasonably indicated to elucidate the nature and/or causality of the SAE. Any follow-up information regarding SAEs must be reported to the Helsinki committee within 24 hours.
Treatment The physician will administer 12.5 mg of MTX diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle. These doses are standard doses of IT treatment with MTX.
Treatments will be scheduled 3 months apart for 1 year .A tota of 4 treatments in a 1 year.
A CBC with differential will be obtained before each treatment to assess the level of hematological suppression.
Laboratory test After obtaining informed consent to perform the procedure, a physician will perform a lumbar puncture with a 25 gauge needle and cerebrospinal fluid (CSF) sample will be obtained and analyze for parameters including cell count and differential, protein and glucose concentration, oligoclonal bands, IgG concentration, cellular analysis by flow cytometry for CD3+, CD20+, CD14+ cell subsets, and measurement of several soluble mediators such as: CXCL13, CD23, light chains, TNFa, IFNg, IL-17, IL-2, IL-10, BDNF and Neurofilaments will be studied by ELISA
MRI scan Brain MRI scan will be done within 1 week before each treatment. The MRI protocol includes the following sequences: T1, T2, FLAIR, T1 will gadolinium, DTI.
Introduction Multiple sclerosis (MS) is characterized pathologically by demyelination, axonal loss, and glial scar formation. Clinically, most patients have a relapsing-remitting course of MS (RRMS) that over time may become progressive without remissions - a secondary progressive MS (SPMS). About 15% of patients have a progressive course from onset which is called primary progressive (PP) (1). In the past decades, several treatments have been approved mainly for the use in RRMS.
Treatments for SPMS may be still effective for the early phase of this course, but it become ineffective for the later phase of SPMS (2,3) For PPMS, there is currently no approved treatment. Thus, more effective therapies need to be developed for treatment of SPMS and PPMS.
Methotrexate (MTX), an anti-metabolite, has been in clinical use since 1948 when it was found to produce temporary remission of acute childhood leukemia. Methotrexate irreversibly binds to and inhibits dihydrofolate reductase, inhibiting the formation of reduced folate, and thymidylate synthetase, resulting in inhibition of purine and thymidylic acid synthesis, thus interfering with DNA synthesis, repair, and cellular replication.
Because of its indirect immunosuppressive effects, MTX is used in treating autoimmune conditions such as rheumatoid arthritis and psoriasis (4). Low dose oral MTX (7.5 mg weekly) was found to be mildly effective, in slowing the deterioration in patients with SPMS (5).
There are accumulating evidences that in progressive MS patients there are follicular lymphoid structures in the meninges and in the Virchow-Robin spaces (8). These follicles are enriched in lymphocytes and dendritic cells which may drive the CNS inflammatory responses in the disease. This CNS restricted immune response may be unaffected by systemic immunomodulation and immunosuppressive therapies. Therefore, intrathecal therapy may target the pathological follicular lymphoid activity.
The safety of intrathecal MTX (ITMTX) has been demonstrated by its widespread use in treating lymphoproliferative diseases and leptomeningeal metastases (9). Sadik et. Al. reported about the feasibility and safety of using intrathecal methotrexate (ITMTX) as a treatment for unresponsive patients with progressive forms of MS (10). In their open label study they found that ITMTX may have a beneficial effect in progressive forms of MS and that it was well tolerated with no serious adverse events.
In the Last year the investigators have treated 8 patients with IT MTX according to the proposed protocol. Until now these patients receive 1-3 therapies of IT MTX without significance adverse event. The adverse event was were reported were: fatigue for several days post therapy and mild headache.
Objective The investigators aim is to evaluate the efficacy , safety and tolerability of intrathecal methotrexate administration in progressive MS patients.
Methods Study Population 30 progressive MS patients Inclusion Criteria
* Age 18-750 years
* Clinically definite diagnosis of MS according to McDonald criteria 2010.
* Progressive disease form defined by confirmed expanded disability status scale (EDSS) progression without relapse by at least 0.5 point or greater in the six months prior to enrollment.
Exclusion criteria
* Pregnancy
* Active infection
* Significant associated medical condition such as malignancy, heart disease or concurrent other autoimmune condition.
* Known allergy to MTX.
* WBC\<4000 cells/µL
* Lym\<800 cells/µL
* Treated with fingolimod or natalizumab 3 months prior to enrollment
Treatment The physician will administer 12.5 mg of MTX diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle. These doses are standard doses of IT treatment with MTX.
Treatments will be scheduled 3 months apart for 1 year .A tota of 4 treatments in a 1 year.
A CBC with differential will be obtained before each treatment to assess the level of hematological suppression.
Evaluation A. Patients will be evaluated every 3 months by a physician other then their treating physician with the following: Kurtzke Expanded Disability Status Scale (EDSS). 25 FW , 9 PHT, Symbol Digit Modalities Test (SDMT), fatigue scale (FSS) and depression scale (BDI). In each of the visits the patient will be asked about adverse events (AE) and will be instructed to report us every AE/ medical complain he will experience between visits.
AEs will be followed until resolution or through completion of the study, whichever comes first. All Serious adverse events (SAEs) will be followed until event resolution, until the condition stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up. The investigator is responsible for ensuring that follow-up includes any supplemental investigations as may be reasonably indicated to elucidate the nature and/or causality of the SAE. Any follow-up information regarding SAEs must be reported to the Helsinki committee within 24 hours.
Treatment The physician will administer 12.5 mg of MTX diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle. These doses are standard doses of IT treatment with MTX.
Treatments will be scheduled 3 months apart for 1 year .A tota of 4 treatments in a 1 year.
A CBC with differential will be obtained before each treatment to assess the level of hematological suppression.
Laboratory test After obtaining informed consent to perform the procedure, a physician will perform a lumbar puncture with a 25 gauge needle and cerebrospinal fluid (CSF) sample will be obtained and analyze for parameters including cell count and differential, protein and glucose concentration, oligoclonal bands, IgG concentration, cellular analysis by flow cytometry for CD3+, CD20+, CD14+ cell subsets, and measurement of several soluble mediators such as: CXCL13, CD23, light chains, TNFa, IFNg, IL-17, IL-2, IL-10, BDNF and Neurofilaments will be studied by ELISA
MRI scan Brain MRI scan will be done within 1 week before each treatment. The MRI protocol includes the following sequences: T1, T2, FLAIR, T1 will gadolinium, DTI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
To Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MS
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Progressive multiple sclerosis
methotrexate
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
Treatment with IT methotrexate
Group Type
EXPERIMENTAL
Intrathecal methotrexate
Intervention Type
DRUG
12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intrathecal methotrexate
12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-75 years
* Clinically definite diagnosis of MS according to McDonald criteria 2010.
* Progressive disease form defined by confirmed expanded disability status scale (EDSS) progression without relapse by at least 0.5 point or greater in the six months prior to enrollment.
* Clinically definite diagnosis of MS according to McDonald criteria 2010.
* Progressive disease form defined by confirmed expanded disability status scale (EDSS) progression without relapse by at least 0.5 point or greater in the six months prior to enrollment.
Exclusion Criteria
* Pregnancy
* Active infection
* Significant associated medical condition such as malignancy, heart disease or concurrent other autoimmune condition.
* Known allergy to MTX.
* WBC\<4000 cells/µL
* Lym\<800 cells/µL
* Treated with fingolimod or natalizumab 3 months prior to enrollment
* Active infection
* Significant associated medical condition such as malignancy, heart disease or concurrent other autoimmune condition.
* Known allergy to MTX.
* WBC\<4000 cells/µL
* Lym\<800 cells/µL
* Treated with fingolimod or natalizumab 3 months prior to enrollment
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tel-Aviv Sourasky Medical Center
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
michal roll
Director R&D Division
Responsibility Role
PRINCIPAL_INVESTIGATOR
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Sadiq SA (2005) Multiple sclerosis. In: Rowland LP (ed) Merritt's neurology, 11th edn. Lippincott Williams and Wilkins, Philadelphia, pp 941-963
Reference Type
BACKGROUND
Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J, Van Dyke C. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995 Jan;37(1):30-40. doi: 10.1002/ana.410370108.
Reference Type
BACKGROUND
Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002 Dec 21-28;360(9350):2018-25. doi: 10.1016/S0140-6736(02)12023-X.
Reference Type
BACKGROUND
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002 Feb;46(2):328-46. doi: 10.1002/art.10148. No abstract available.
Reference Type
BACKGROUND
Ashtari F, Savoj MR. Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon beta-1alpha: A randomized controlled trial. J Res Med Sci. 2011 Apr;16(4):457-62.
Reference Type
BACKGROUND
Currier RD, Haerer AF, Meydrech EF. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry. 1993 Nov;56(11):1217-8. doi: 10.1136/jnnp.56.11.1217.
Reference Type
BACKGROUND
Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007 Apr;130(Pt 4):1089-104. doi: 10.1093/brain/awm038.
Reference Type
BACKGROUND
Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology. 1994 Aug;44(8):1463-9. doi: 10.1212/wnl.44.8.1463.
Reference Type
BACKGROUND
Sadiq SA, Simon EV, Puccio LM. Intrathecal methotrexate treatment in multiple sclerosis. J Neurol. 2010 Nov;257(11):1806-11. doi: 10.1007/s00415-010-5614-4. Epub 2010 Jun 10.
Reference Type
BACKGROUND
Kolb H, Shachaf Y, Fainberg K, Golan M, Regev K, Vigiser I, Fuchs L, Gadoth A, Kestenbaum M, Omer N, Shopin L, Ash EL, Artzi M, Ben Bashat D, Aizenstein O, Karni A. Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up. J Neurol. 2025 May 4;272(5):374. doi: 10.1007/s00415-025-13114-z.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0166-15-TLV
Identifier Type: -
Identifier Source: org_study_id